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Abstract
Objective: The red cell membrane of sickle cell anaemia is vulnerable to attack from the alternative 
complement pathway. The activation of the alternative complement pathway is initiated by 
externalization of phosphatidylserine on red cell membrane. Serum and cell bound regulators normally 
prevent amplification of the cascade. However, red blood cells in sickle cell anaemia appear to be exposed 
and the cell lysing membrane attack complex is ubiquitous on irreversible sickle red blood cells. It is 
possible that there are deficiencies (either functional or quantitative) of complement regulators. In this 
study the quantitative defects of the most abundant serum phase regulator, complement factor H in sickle 
cell anaemia was investigated. 
Methods: We compared the plasma levels of complement factor H (a serum phase regulator of the 
alternative pathway) in 61 steady state Hb SS with 60 healthy Hb AA using an enzyme linked 
immunosorbent assay to analyze complement factor H level in the plasma. The full blood count 
parameters were estimated using flow cytometry.
Results: There was no significant difference in the serum complement factor H levels between the steady 
state Hb SS and healthy Hb AA. Significant inverse relationships existed between complement factor H, 
total white cell count, granulocyte cell count and platelet count as well as significant direct relationships 
between complement factor H, haematocrit, and the haemoglobin concentration.
Conclusion: Complement factor H in patients with sickle cell anaemia who are in steady state is not 
significantly lower than in controls.
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Les niveaux du facteur H du complément dans l'état stable de la 
drépanocytose. 
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Résumé
Objectif: La membrane érythrocytaire de la drépanocytose est vulnérable aux attaques provenant de la 
voie alterne. L'activation de la voie alterne est initiée par l'extériorisation de la phosphatidylsérine sur la 
membrane érythrocytaire. Le sérum et la cellule sont des régulateurs liés pour prévenir généralement 
l'amplification de la cascade. Cependant, les globules rouges atteints de drépanocytose apparaissent 
comme étant exposés et le complexe d'attaque membranaire de la lyse cellulaire est omniprésent dans le 
cas de l'anémie falciforme irréversible. Il est possible qu'il y ait des déficiences (soit fonctionnelles, soit 
quantitatives) de régulateurs du complément. Dans cette étude, les défauts quantitatifs du sérum le plus 
abondant de la phase régulatrice, le facteur H du complément dans la drépanocytose, ont été examinés. 
Méthodes: Nous avons comparé le taux plasmatique du facteur H du complément (un sérum régulateur de 
phase de la voie alterne) chez 61 états stables Hb SS disposant de 60 Hb AA sains, en utilisant la méthode 
immuno-enzymatique pour analyser le niveau du facteur H du complément dans le plasma. La 
numérotation globulaire (hémogramme) a été estimée en utilisant la cytométrie en flux. 
Résultats : Il n'y a pas de différence significative en ce qui concerne les niveaux du sérum facteur H du 
complément, entre l'état stable Hb SS et le Hb AA sain. A l'inverse, un lien significatif existe entre le 
facteur H du complément, le nombre total de globules blancs, de granulocytes et de plaquettes. Une 
relation significative directe est également établie entre le facteur H du complément, l'hématocrite et la 
concentration d'hémoglobine. 
Conclusion : le facteur H du complément chez les patients en état stable atteints de drépanocytose est 
guère inférieur à celui enregistré lors des contrôles. 
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INTRODUCTION
The sickle cell anaemia individual 
endures lifelong haemolysis due to the formation 
of insoluble haemoglobin S polymers and 
irreversible damage to the red cell membrane, 
punctuated by intermittent acute crises which 
culminates in chronic end organ damage (1). The 
cause of sickle cell anaemia is the homozygous 
inheritance of the sickle gene.  The sickle gene is 
a point mutation in the beta globin gene on exon 1 
resulting in a change from GAG to GTG (2).  The 
resulting sickle haemoglobin has replaced 
glutamic acid with valine at position 6 of the beta 
globin polypeptide (3).  The sickle haemoglobin 
forms polymers  under  condi t ions  of  
deoxygenation. Within milliseconds to seconds 
these polymers grow exponentially (4). Although 
on re-exposure to oxygen the polymers dissolve, 
repea ted  cyc les  of  oxygenat ion  and  
deoxygenation makes the polymers insoluble and 
rigid (5). The rigid form of the S polymer 
damages the  red cell membrane, and assumes  an 
irreversibly sickled shape (6). Furthermore, 
damaged red cell membrane  exteriorizes 
phosphatidylserine to the external surface of the 
erythrocyte membrane (6,7). The activation of 
complement pathway is accelerated by the 
abnormally situated phosphatidyl serine on the 
external surface of the red cell membrane (8). 
Plasma C3 levels are consumed and activator 
complement proteins specific to the alternative 
pathway- Factor B is significantly depleted in 
sickle cell anaemia (8). On dense and irreversibly 
sickled red cells, increased amounts of C5  - C7 b
and C9 (components of the membrane attack 
complex) confirms the amplification and 
completion of the alternative complement 
pathway (9). Exposure of red blood cells to 
activated complement proteins can lead either to 
extravascular haemolysis as occurs in immune 
mediated haemolytic anaemia or intravascular 
haemolysis as occurs in Paroxysmal nocturnal 
haemoglobinuria (10,11).
The complement pathway is a part of our 
bodies innate defence system. It monitors the 
blood, attacking and removing foreign bodies and 
organisms. The system is made up of 30 soluble 
proteins which circulate as inactive precursors 
(12). Once activated with the aid of convertases, 
the system is propagated through three pathways 
(the classical, the lectin and the alternative 
pathway) (13). The alternative complement 
pathway is initiated by spontaneous hydrolysis of 
C3's internal thioester bond. It occurs on both 
host and foreign cells. The hydrolysed C3(H2O) 
together with proteins Factor B and D form 
C3convertase (C3 H2OBb). The C3 convertase 
cleaves C3 to C3a and C3b. C3b binds to host 
surfaces and sets up an amplification loop where 
many more C3b are produced which couple with 
Factor B.  C3bBb together with properdin (from 
neutrophils) forms C5 convertase which cleaves 
C5  to C5a and C5b.(14) The C5b joins C3BbP to 
activate C6, C7, C8 and they result in the 
assembly of C9 into the Membrane Attach 
Complex that creates a pore in the cell (14). See 
Figure 1
Because the alternate pathway has a 
spontaneous tick over mechanism, C3b is 
deposited on both host and pathogen surfaces 
alike. When alternate complement system is 
activated on sickle cells initiated by the 
externalization of phosphatidyl serine, 
homeostatic mechanisms specific to the 
alternative pathway should kick in. Factor H is 
one of the most important plasma complement 
regulators (15). Factor H regulates the binding of 
hydrolysed C3, C3(H2O) and C3bBb by 
promoting their rapid decay and short-circuiting 
the amplification loop. It works with factor I (a 
cell bound regulator) to inactivate any C3b that 
escaped the initial deactivation., In effect, the 
terminal cascade is shut down. Factor H is 
catalyzed in its regulatory activity and 
concentration rapidly decreases where ever 
widespread inactivation of C3 convertase is 
required (12). In atypical haemolytic uraemic 
syndrome (aHUS), age-related macular 
degeneration (AMD) and membranoproliferative 
glomerulonephritis (MPGN), mutations of 
complement factor H results in the deposition of 
C3b on membranes of the retina and glomeruli 
(16). Quantitative complement factor H 
deficiency (CFHD) manifests as asymptomatic, 
recurrent bacterial infections, and renal failure 
(17).
 In sickle cell anaemia, evidence of 
alternative complement pathway activation 
observed include the following: C3b is bound to 
sickle erythrocytes membrane (6), Factor B and 
Factor D concentrations (specific to the alternate 
pathway) reduced to half that of normal controls 
(18). Our hypothesis is that complement factor H 
is depleted in sickle cell anemia while playing its 
regulatory role. In view of the aforementioned, 
we measured complement factor H in sickle cell 
anemia patients and compared with controls to 
see if this regulator is truly depleted. 
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MATERIALS AND METHODS
Study population: Sixty-one (61) adult 
haemoglobin-S patients in steady state and 60 
healthy age and sex matched adult haemoglobin-
A blood donors from the Oyo State Blood Bank, 
as well as volunteer medical and nursing staff 
were recruited. The ages of the sickle cell patients 
range between 14 and 52 years while those of the 
controls were between 15 and 60 years. The study 
was conducted over a 3-month period. 
Haemoglobin electrophoresis were confirmed 
using Agarose gel electrophoresis at alkaline pH 
of 8.4. Steady-state was defined as having no 
blood transfusions in the previous four months 
and absence of acute episodes of the following; 
infection, vaso-occlusive crises, acute coronary 
syndrome, stroke, priapism, acute splenic 
sequestration for at least one month before 
inclusion in the study (19). Sickle cell anaemia 
patients with a diagnosis of glomerulonephritis or 
age related macular degeneration were excluded 
from the study. 
Ethical Considerations: Ethical approval was 
obtained from the Oyo State Research and Ethics 
Committee.
Sample collection and analysis: 
Informed consent was obtained from the 
participants.  Interviewer administered 
questionnaires were used to obtain information 
o n  s o c i o - d e m o g r a p h i c  a n d  c l i n i c a l  
characteristics such as previous admissions for 
febrile illnesses and blood transfusion from study 
participants. Five millilitres of venous blood 
were collected into each of 2 different pottasium 
ethylene diaminetetra acetic (K EDTA) bottles 
for full blood count (FBC) and complement 
Factor H analysis respectively.   The blood 
sample for complement factor H analysis was 
centrifuged at 2000 g for five minutes within 30 
minutes of collection. The plasma was decanted 
using a plastic pipette and stored at -20°C till 
analysis. The plasma complement factor H level 
was determined by the enzyme linked 
immunosorbent assay method using the abcam 
ab137975 Factor H Human ELISA kit (abcam 
Limited UK). 
Statistical analysis: Student t- test was 
used to compare the mean of Complement Factor 
H.  Correlation testing was carried out using the 
Pearson's correlation test on complement factor 
H and full blood count. 
RESULTS
A total of 121 subjects participated in the 
study. These included 61 patients with sickle cell 
anaemia and 60 haemoglobins A controls. The 
mean age of the patients was 24.5 ± 10.1 and the 
control was 24.5 ± 6.6 (Table1). Clinical 
characteristics of patients with sickle cell 
anaemia are shown in table 2 and ninety point two 
percent (90.2%) of the patients had ever been 
hospitalised while sixty point seven percent 
(60.7%) of the patients had ever been transfused. 
Table 3 shows the mean of the haematological 
parameters of both patients and controls. 
Complement factor H value was slightly lower in 
the SCA patients compared with the controls and 
it was not statistically significant (p=0.14). 
(Table 4) There was no significant relationship 
between complement factor H and clinical 
features of patients (Table 5). The white cell 
count and granulocyte counts had a significant 
negative correlation with complement factor H 
(p=0.0002 and p=0.002 respectively) (Table 6).  
There was greater variability in the complement 
factor H levels among the controls compared with 
the patients (Figure 2). 
DISCUSSION
This study compared the complement 
factor H level of patients with sickle cell anaemia 
with controls and found that there was no 
significant difference between SCA and controls. 
In sickle cell anaemia there is persistent, 
increased activation of the alternate system 
which progresses to formation of the membrane 
attack complex on the sickled red cells. This is 
clear from the reduction of alternative pathway 
activator protein factor B and D and C3b coated 
red cell (particularly the dense and irreversibly 
sickle red blood cells) found in these groups of 
patients. We therefore assayed the most abundant 
regulatory protein of the alternative complement 
system complement factor H that works both in 
the fluid and the cell bound phase. Recent 
findings shows that deficiencies and mutations in 
the structure of the complement factor H results 
in deposition of C3b on tissue surfaces and 
extracellular matrices (20).  Because sickle cell 
anaemia has both a decrease in serum factor B 
and increased C3b present on red cell membranes 
we surmised that, like atypical haemolytic uremic 
s y n d r o m e  o r  m e m b r a n o p r o l i f e r a t i v e  
glomerulonephritis, the answer may lie in either a 
quantitative or qualitative deficiency of 
complement factor H (21). From this study, 
however, complement factor H levels are not 
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significantly lower among sickle cell anaemia 
individuals and haemoglobin A controls. The 
persistence activation of the alternative 
complement activation is not associated with 
quantitative deficiencies in complement factor H 
levels. The factor H levels are comparable with 
those of normal individuals who do not have C3b 
on red cell surfaces. For one thing, it reassures the 
researchers that regulatory mechanisms of the 
complement pathway in sickle cell anaemia 
remain intact. On the other hand, the fact that 
complement factor H is not reduced in sickle cell 
anaemia suggest that the sheer number of the C3b 
molecules bound to sickle erythrocytes defies 
total regulation. These may provide research 
questions for the future.
We found that there was higher 
variability of complement factor H levels in the 
controls compared with SCA. Apparently healthy 
control may have a higher variability in their 
genetic material or a greater variability in the 
external environment which they inhabit 
compared with the haemoglobin S population 
sampled in this study. 
The white cell count and neutrophil 
count was inversely related to Factor H. Zwede et 
al found that an important initiator of the 
alternative complement pathway was neutrophil 
produced properidine (13). They found that  
properdine acts to stabilize the alternative 
pathway and is a positive regulator of the 
alternate pathway. If properdine concentrations 
are increased, the amplification of the alternative 
complement pathway is assured. An inverse 
relationship between the white cells and 
complement factor suggests that the alternative 
complement pathway aided by properdine 
outstrips the regulatory mechanisms. Prior to this 
study no relationship has been documented 
between haematological parameters and 
complement factor H amongst sickle cell 
anaemia patients.
 There was also a negative correlation 
between complement factor H and platelet count 
although the correlation was not statistically 
significant. Miao et al describes the role of 
platelets in immunology through their ability to 
bind complement proteins, and initiate 
complement activation (22). The negative 
correlation between platelet count and 
complement factor H is an example of the 
complement activation that overwhelms 
regulatory mechanisms. We discovered 
significant direct relationship between 
haematocrit, haemoglobin concentration and 
complement factor H concentrations. This 
suggests that complement induced haemolysis 
plays a role in the aetiology of anaemia in sickle 
cell anaemia. If the complement cascade is kept 
under tight control, complement mediated lysis is 
minimized. Higher MCV values were also found 
to be associated with lower complement factor H 
level. The exact pathophysiologic mechanism is 
yet to be elucidated and provides interesting 
research questions in the relationship between the 
alternative complement pathway and sickle cell 
anaemia for the future. 
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        Patients n=61       Controls n=60   
 Number  Percentage 
(%) 
Number  Percentage 
(%) 
×2 P value 
Gender        
Male  24 40 20 33   
Female  37 60 40 67 0.48 0.49 
 
Age group (years) 
      
=25 35 57.4 49 81.7   
26-35 19 31.1 7 11.7   
36-45 3 4.9 2 3.3 9.26 0.06 
46-55 3 4.9 2 3.3   
>56 1 1.6 0 0   
Mean age ±sd 24.5  ± 10.1  24.5 ±  6.6 0.5 0.5 
 
Tribe  
      
Yoruba  49 80.3 48 80   
Others  12 19.7 12 20 1.06 0.6 
 
Educational status 
      
None  2 3.3 5 8.3   
Primary  6 9.8 1 1.7   
Secondary  39 63.9 2 3.3   







Table 2: Clinical characteristics of patients 
 
Clinical characteristics  Response Number  Percentage% 
Fever in the last year Yes 25 41 
No  36 59 
 
Infection in the last year Yes  8 13.1 
No  53 86.9 
 
Type of infection Urinary tract infection 2 3.3 




Transfusion history(ever) Yes 37 60.7 
No 24 39.3 
 
History of chronic leg ulcer Yes 3 4.9 
No  58 95.1 
 
History of hospitalization 
(ever) 
Yes  55 90.2 
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Table 3:  Haematological Parameters of sickle cell anaemia patients and controls 
 





T value P value 
Haematocrit  (%) 24.3(6.2) 37.3(6.7) 11.09 0.00* 
Haemoglobin concentration (g/L) 77.5(18.6) 119.0(25.4) 10.49 0.00* 
White blood cells (×109/L) 12.8(4.6) 5.7(1.8) -11.06 0.00* 
Neutrophil count (×109/L) 5.8(2.4) 2.6(1.0) -10.13 0.00* 
Lymphocyte count (×109/L) 5.5(2.7) 2.54(1.3) -7.69 0.00* 
Monocyte count (×109/L) 3.0(1.3) 0.6(0.3) -1.44 0.15 
Platelet count (×109/L) 366(129) 236(72) -6.85 0.00* 
Mean Corpuscular Volume (fL) 91.3(10.7) 83.9(5.9) -4.70 0.00* 
Mean Corpuscular Haemoglobin (pg) 29.3(3.8) 27.1(3.0) -3.47 0.001* 
Mean Corpuscular Haemoglobin 
Concentration (g/L) 
321(19) 323(27.8) 0.53 
0.59 
*<0.05 significant 





Table 4:  Complement Factor H in sickle cell anaemia patients  and controls 
 
Variables  Sickle cell anaemia  
mean(sd) 
Controls  mean(sd) T test   P value 
Complement Factor H(ng/mL) 2.4 (1.3) 2.8 (1.6) 1.5 0.14 
Total   61 60   
<0.05 *significant 
>0.05 not significant 





Table 5: Association between plasma complement factor  
H levels and clinical characteristics of sickle cell anaemia patients 
 
Clinical characteristics ×2 value P value 
Previous hospital admission 55.4 0.5 
Positive history of fever in the last 
year 
56.6 0.5 
History of infection in the last one 
year 
56.6 0.5 
History of blood transfusion in the 
last year 
52.1 0.6 
History of chronic liver disease 61.0 0.3 
*<0.05 significant 
>0.05 not Significant 
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Table 6: Relationship  between complement factor H, 
and haematological  parameters in sickle cell patients 
 
Parameter  R P value 
White blood cell count (x 109/L) -0.21 0.002* 
Lymphocyte count (x 109/L) -0.07 0.44 
Monocyte count (x109/L) -0.02 0.81 
Granulocyte count (x 109/L) -0.28 0.002* 
Haemoglobin g/L -0.16 0.08 
Haematocrit % -0.14 0.13 
MCV(fL) -0.18 0.05 
MCH (pg) 0.07 0.45 
MCHC(g/dL) 0.16 0.09 
Platelet count (x109/L) -0.07 0.05 
*<0.05 significant 
>0.05 not Significant 
MCV= mean corpuscular volume 
MCH= Mean corpuscular haemoglobin  
MCHC= mean corpuscular haemoglobin concentration 
 
  
Fig 1: The initiation of the cascade of the complement pathway and its endpoint. 
https://www.researchgate.net/profile/Horea_Rus/publication/51579775/figure/fig1/AS:285283066757120@
1445028191660/Complement-activation-pathways-and-assembly-of-the-terminal-pathway.png 




Figure 2: Complement Factor H levels in haemoglobin A and haemoglobin S 
This box plot illustrates median values of complement factor H in patients and control. The median 
complement factor H level for patients was 2.8 ng/mL and for controls was 3.2 ng/mL 
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